<?xml version="1.0" encoding="UTF-8"?>
<p>Arbidol is utilized as a unique anti-viral candidate that has revealed a robust in-vitro influence in suppressing the replication of the SARS-CoV.
 <sup>
  <xref rid="cit0021" ref-type="bibr">21</xref>
 </sup> Case reports evidenced the anti-viral potency of sole arbidol or in blend with other drugs when used for dealing with pneumonia caused by SARS-CoV-2.
 <sup>
  <xref rid="cit0022" ref-type="bibr">22</xref>-
  <xref rid="cit0026" ref-type="bibr">26</xref>
 </sup> Presently, many clinical control trials are being executed to examine the effectiveness of arbidol against SARS-CoV-2. Remdesivir is a nucleoside analogue GS-5734 with broad-spectrum activity to suppress SARS-CoV and MERS-CoV 
 <italic>in vivo</italic>.
 <sup>
  <xref rid="cit0027" ref-type="bibr">27</xref>,
  <xref rid="cit0028" ref-type="bibr">28</xref>
 </sup> It strappingly prevented SARS-CoV-2 infection in a recent 
 <italic>in vitro</italic> investigation at low-micro molar concentration accompanied by a high selectivity index.
 <sup>
  <xref rid="cit0022" ref-type="bibr">22</xref>
 </sup> Moreover, the first patient of COVID-19 in the United States was successfully treated by the intravenous administration of remdesivir.
 <sup>
  <xref rid="cit0029" ref-type="bibr">29</xref>
 </sup> Though remdesivir exhibits many merits for curing SARS-CoV-2 infection and pneumonia, randomized controlled trials (RCTs) are still necessitated to prove its effectiveness and safety status.
</p>
